These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38045624)

  • 1. P2RY13 is a prognostic biomarker and associated with immune infiltrates in renal clear cell carcinoma: A comprehensive bioinformatic study.
    Chu J; Liu W; Hu X; Zhang H; Jiang J
    Health Sci Rep; 2023 Dec; 6(12):e1646. PubMed ID: 38045624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of gasdermin D in clear cell renal cell carcinoma and its effect on its biological function.
    Zhang J; Wang Y; Ma J; Aimudula A
    Front Oncol; 2023; 13():1163714. PubMed ID: 37483501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction and analysis of novel key genes ITGAX, LAPTM5, SERPINE1 in clear cell renal cell carcinoma through bioinformatics analysis.
    Sui Y; Lu K; Fu L
    PeerJ; 2021; 9():e11272. PubMed ID: 33976979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma.
    Meng W; Chen B; Jiang Z; Cai B; Ma L; Guan Y
    Transl Cancer Res; 2023 Aug; 12(8):2071-2098. PubMed ID: 37701098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive analysis of the prognostic value and immune infiltration of low expression DBT in clear cell renal cell carcinoma.
    Xie W; Xi P; Liu Y; Zhang Z; Sun T
    Front Pharmacol; 2022; 13():1002588. PubMed ID: 36299888
    [No Abstract]   [Full Text] [Related]  

  • 7. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
    Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
    Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated bioinformatics analysis to identify the key gene associated with metastatic clear cell renal cell carcinoma.
    Miao S; Song J; Liu Q; Lai J; Wang H; Ran L
    Med Oncol; 2022 Jun; 39(9):128. PubMed ID: 35716215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of CXCL10 as a Prognostic Biomarker for Clear Cell Renal Cell Carcinoma.
    Qu G; Wang H; Yan H; Liu G; Wu M
    Front Oncol; 2022; 12():857619. PubMed ID: 35296026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
    Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
    Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases.
    Li J; Cao J; Li P; Deng R; Yao Z; Ying L; Tian J
    Int J Gen Med; 2022; 15():325-342. PubMed ID: 35035230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUDT1 Could Be a Prognostic Biomarker and Correlated with Immune Infiltration in Clear Cell Renal Cell Carcinoma.
    Lin Y; Zhang F; Jin Y; Zhong Q; Tan W; Liu J; Wu Z
    Appl Bionics Biomech; 2022; 2022():3669296. PubMed ID: 36606241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of bioinformatics analysis to identify possible hub genes and important pathways associated with clear cell renal cell carcinoma.
    Kumar A; Yadav RP; Chatterjee S; Das M; Pal DK
    Urologia; 2024 May; 91(2):261-269. PubMed ID: 38159064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma.
    Bao L; Zhao Y; Liu C; Cao Q; Huang Y; Chen K; Song Z
    J Cancer; 2020; 11(7):1712-1726. PubMed ID: 32194783
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics analysis of C3 and CXCR4 demonstrates their potential as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC).
    Quan J; Bai Y; Yang Y; Han EL; Bai H; Zhang Q; Zhang D
    BMC Cancer; 2021 Jul; 21(1):814. PubMed ID: 34266404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma.
    Zhang Y; Hua X; Shi H; Zhang L; Xiao H; Liang C
    Cancer Cell Int; 2021 Dec; 21(1):680. PubMed ID: 34923969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of significant genes with prognostic influence in clear cell renal cell carcinoma via bioinformatics analysis.
    Zhang F; Wu P; Wang Y; Zhang M; Wang X; Wang T; Li S; Wei D
    Transl Androl Urol; 2020 Apr; 9(2):452-461. PubMed ID: 32420151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LGALS1 was related to the prognosis of clear cell renal cell carcinoma identified by weighted correlation gene network analysis combined with differential gene expression analysis.
    Fang J; Wang X; Xie J; Zhang X; Xiao Y; Li J; Luo G
    Front Genet; 2022; 13():1046164. PubMed ID: 36712844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.